Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Siltuximab (Primary)
- Indications Giant lymph node hyperplasia; Multiple myeloma; Paraproteinaemia
- Focus Pharmacodynamics
- 16 Jan 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.